Benign prostatic hyperplasia (BPH) - Pipeline Insight, 2020

Publisher Name :
Date: 24-Nov-2020
No. of pages: 80
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's, " Benign Prostatic Hyperplasia - Pipeline Insight, 2020," report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Benign Prostatic Hyperplasia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

- Global coverage

Benign Prostatic Hyperplasia: Understanding

Benign prostatic hyperplasia: Overview

Benign prostatic hyperplasia (BPH) refers to the change in the size of the prostate and not the potential symptoms that it may cause, which are usually referred to as lower urinary tract symptoms (LUTS). LUTS may be primarily irritative, obstructive, or mixed. Men with BPH may be asymptomatic, respond to lifestyle changes, or require medical or surgical therapy; symptoms are more common as men age.

Symptoms

The symptoms of Benign prostatic hyperplasia include:

- Obstructive Symptoms - Sensation of incomplete bladder emptying, Straining to void,Urinary hesitancy, Weak urinary stream

- Irritative Symptoms - Dysuria, Nocturia, Urinary frequency, Urinary urgency

Diagnosis

Several key diagnostic tools and investigations are used to diagnose BPH in men who present with LUTS. The first and most important tool in the assessment and diagnosis of BPH is the medical history of the patient. By taking a detailed history, one can establish potential causes and relevant comorbidities of LUTS, some of which might contribute to LUTS. A physical examination, including a digital rectal examination (DRE) and urinalysis, is the next step in diagnosis. Further investigations, such as uroflowmetry and measuring PVR volume, should help to confirm the presence of obstructive symptoms attributable to BPH.

Treatment

Pharmacologic treatment- Men with moderate to severe LUTS from BPH (AUASI score of 8 or higher) or mild LUTS that are deemed bothersome by the patient may be offered pharmacologic treatment. The 2 major classes of medications for BPH are alpha-adrenergic blockers and 5-alpha reductase inhibitors. The PDE-5 inhibitor tadalafil is also approved by the Food and Drug Administration (FDA) for the treatment of BPH.

Non Pharmacologic treatment- In men with mild LUTS symptoms from BPH (usually defined as an AUASI score of 0-7), medical or surgical treatment is not required. In the Medical Therapy of Prostatic Symptoms Study,23 fewer than 5% of men with mild symptoms who did not receive treatment had a progression of their symptoms as defined by a 4-point or greater increase in their AUASI score. No cases of acute kidney injury due to obstructive uropathy occurred.

Benign prostatic hyperplasia Emerging Drugs Chapters

This segment of the Benign prostatic hyperplasia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Benign prostatic hyperplasia Emerging Drugs

- Topsalysin: Sophiris Bio

Topsalysin is a modified pore forming protein (proaerolysin) in phase III clinical trials for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. It was developed by Sophiris Bio, then licensed to Kissei for development.

- OPK88004: Eli Lilly and Company

OPK88004 is a Phase 2 drug that is a selective androgen receptor modulator. OPK-88004 has the ability to serve as an antagonist to androgen receptors in the prostate, resulting in decreased prostate specific antigen (PSA) levels, and as an agonist resulting in increased anabolic effects, such as increased lean body mass and physical function and decreased fat mass. The originator of this was Eli Lilly and now licensed by OPKO Health.

Further product details are provided in the report……..

Benign prostatic hyperplasia: Therapeutic Assessment

This segment of the report provides insights about the different Benign prostatic hyperplasia drugs segregated based on following parameters that define the scope of the report, such as:

- Major Players in Benign prostatic hyperplasia

There are approx. 30+ key companies which are developing the therapies for Benign prostatic hyperplasia. The companies which have their Benign prostatic hyperplasia drug candidates in the most advanced stage, i.e. phase III include, Sophiris Bio.

- Phases

DelveInsight's report covers around 30+ products under different phases of clinical development like

- Late stage products (Phase III)

- Mid-stage products (Phase II)

- Early-stage product (Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

- Route of Administration

Benign prostatic hyperplasia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

- Oral

- Parenteral

- intravitreal

- Subretinal

- Topical.

- Molecule Type

Products have been categorized under various Molecule types such as

- Monoclonal Antibody

- Peptides

- Polymer

- Small molecule

- Gene therapy

- Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Benign prostrate hyperplasia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Benign prostatic hyperplasia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Benign prostatic hyperplasia drugs.

Report Highlights

- The companies and academics are working to assess challenges and seek opportunities that could influence Benign prostatic hyperplasia R&D. The therapies under development are focused on novel approaches to treat/improve Benign prostatic hyperplasia.

- In November 2020, Urovant Sciences has agreed to be fully acquired by largest investor and close partner Sumitovant BioPharma and the deal is set to be finalized in early 2021.

Benign prostatic hyperplasia Report Insights

- Benign prostatic hyperplasia Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Benign prostatic hyperplasia Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

- How many companies are developing Benign prostatic hyperplasia s drugs?

- How many Benign prostatic hyperplasia drugs are developed by each company?

- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Benign prostatic hyperplasia?

- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Benign prostatic hyperplasia therapeutics?

- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

- What are the clinical studies going on for Benign prostatic hyperplasia and their status?

- What are the key designations that have been granted to the emerging drugs?

Key Players

- ASKA Pharmaceutical

- Otsuka Pharmaceutical

- Eli Lilly and Company

- XuanZhu Pharma

- Aiviva BioPharma

- Veru Helathcare

- Boryung Pharmaceutical

Key Products

- AKP009

- Tolvaptan

- OPK88004

- Fadanafil

- lenvatinib

- Tamsulosin

- BR9006

Benign prostatic hyperplasia (BPH) - Pipeline Insight, 2020

Table of Contents

Introduction
Executive Summary
Benign prostatic hyperplasia: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Benign prostatic hyperplasia - DelveInsight's Analytical Perspective
In-depth Commercial Assessment
• Benign prostatic hyperplasia companies' collaborations, Licensing, Acquisition -Deal Value Trends
Benign prostatic hyperplasia Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Topsalysin: Sophiris Bio
• Product Description
• Research and Development
• Product Development Activities
Mid Stage Products (Phase II)
• Comparative Analysis
OPK88004: Eli lilly and Company
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
Fadanafil: XuanZhu Pharma
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
Lenvatinib: Aiviva BioPharma
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Benign prostatic hyperplasia Key Companies
Benign prostatic hyperplasia Key Products
Benign prostatic hyperplasia - Unmet Needs
Benign prostatic hyperplasia - Market Drivers and Barriers
Benign prostatic hyperplasia - Future Perspectives and Conclusion
Benign prostatic hyperplasia Analyst Views
Benign prostatic hyperplasia Key Companies
Appendix


List of Tables

Table 1 Total Products for Benign prostatic hyperplasia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products


List of Figures

Figure 1 Total Products for Benign prostatic hyperplasia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
  • Global Recombinant Human Erythropoietin (rhEPO) Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 99
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - ESRD - Cancer - HIV - Wounds and Neural Disease Segment by Application - Hospi......
  • Global rhEPO Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 97
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - ESRD - Cancer - HIV - Wounds and neural disease Segment by Application - Hospi......
  • Global Rhematoid Arthritis Drugs Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 94
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Pharmaceuticals - Biopharmaceuticals Segment by Application - Prescription - OTC......
  • Global Chronic Obstructive Pulmonary Disease Drugs Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 118
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Inhalers - Nebulizers Segment by Application - Emphysema - Chronic Bronchitis ......
  • Global Chronic Lymphocytic Leukemia Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 121
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Acutemyeloid (ormyelogenous)leukemia (AML) - Chronicmyeloid (ormyelogenous)leukemia (CML) - Acutelymphocyti......
  • Global Chemotherapy-induced Nausea and Vomiting Drugs Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 93
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - 5-HT3 Inhibitors - NK1 Inhibitors - Other Segment by Application - Highly Emetogenic ......
  • Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 120
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Aloxi (Palonosetron) - Kytril Generic (Granisetron) - Emend (Aprepitant) - Akynzeo (Netupitant-Palon......
  • Global ß-blockers Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 122
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Nonselective Agents - Selective Agents Segment by Application - Abnormal Heart Rhythms......
  • Global a-adrenoreceptor Antagonists Market Research Report 2021
    Published: 15-Jan-2021        Price: US 2900 Onwards        Pages: 116
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type - Non-selective Antagonists - Selective Antagonists Segment by Application - Hypertension......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs